Sinopharm COVID-19 vaccine (The Beijing Institute of Biological Products, Sinopharm vaccine is a vaccine that aims to protect against COVID-19. Manufacturer/developer: Beijing Institute of Biological Products - Research name: BBIBP-CorV
I want to know if there are scientific publications with reference on the subject (Sinopharm vaccine // Research: BBIBP-CorV).
I only find news in newspapers or informal publications.
Dear Dr. Espinosa!
You raised a very important issue. There is an emerging fear that Sinopharm is less effective than the other available vaccines. I really think there is a need foe further studies to examine this matter. The objective is to have a such a mix of vaccines at hand that could protect against the variants of COVID-19. In emergency situation in a country even brand new vaccines that are within Phase III trials can be taken into use:
1) Tanya Lewis (2021). Should We Change COVID Vaccine Doses to Reach More People? What the Data Say: Scientists are debating whether to delay, skip or halve doses. But untested tweaks could shake public confidence, Scientific American, 14 January 2021, © 2021 Scientific American, a Division of Springer Nature America, Inc.Open access: https://www.scientificamerican.com/article/should-we-change-covid-vaccine-doses-to-reach-more-people-what-the-data-say1/
2) Saborni Chakraborty et al. (2021).SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand? Advanced Drug Delivery Reviews, Volume 172, May 2021, Pages 314-338 Open access: Article SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
3) Olivier J Wouters et al. (2021). Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment, THE LANCET Health Policy, Volume 397, Issue 10278, March 13, 2021, Open access: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00306-8/fulltext
My country of origin is Hungary, and they use Sinopharm there, but as till today 16 April I have not heard any reported cases that this Chinese vaccine would be significantly less effective compared to the other vaccines in use in Hungary. I follow the news and scientific community online information exchange every day. Yours sincerely, Bulcsu Szekely
Have a look at this useful link.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30831-8/fulltext
SINOPHARM (BBIBP-CorV) phase 3 trials included 31,000 volunteers across 125 nationalities in the UAE alone. The UAE’s Ministry of Health and Prevention reviewed Sinopharm interim analysis of the phase 3 trials, which showed Sinopharm inactivated vaccine have 86% efficacy against COVID-19 infection. The vaccine has a 99% seroconversion rate of NAb and 100% effectiveness in preventing moderate and severe cases of the disease.
Article COVID-19 Vaccines: Current Status and Implication for Use in Indonesia
Variable and unverified Sinopharm COVID-19 Vaccine Phase III Results in Brazil, Turkey, Indonesia, and UAE
The article referred to by Dr. Arvind Singh was a Phase 1/2 trial of Sinopharm COVID-19 vaccine published in Lancet.
There has been considerable variability in reporting efficacy data for Sinopharm COVID-19 Vaccine in phase III trials in the media only without any publication in a peer reviewed medical Journal.
Data presented from the most complete dataset from trials in Brazil showed it to be about 78% effective in preventing mild cases and 100% effective in staving off moderate to serious cases (1).
In trials in Turkey, the vaccine was 91.25% effective, while in Indonesia, it was 65.3% effective. These interim results need to be verified and thoroughly examined. Data are scant on this vaccine with two figures appearing on interim vaccine data efficacy reported (2). Earlier data had indicated an 86% efficacy in UAE (3) )
1. https://www.bbc.com/news/world-latin-america-55642648
2. https://www.reuters.com/article/health-coronavirus-vaccine-china-idUSKBN297035.
3. https: //www.reuters.com/article/health-coronavirus-china-vaccine-int-idUSKBN2940CA
Kindly please find the following link (Looking beyond COVID-19 vaccine phase 3 trials) published in nature:
https://www.nature.com/articles/s41591-021-01230-y